A New Era for Pancreatic Cancer: Daraxonrasib Nearly Doubles Survival in Phase 3 Trial

For decades, pancreatic cancer has been one of the most challenging malignancies to treat, largely because the primary driver of the disease—the KRAS mutation—was long considered “undruggable.” Yet, a significant shift is underway. Recent results from a pivotal Phase 3 clinical trial suggest that a new class of inhibitors is finally breaking through, offering a meaningful increase in survival for patients with advanced disease.

The RASolute 302 Trial: Unprecedented Results

In mid-April, Revolution Medicines announced positive results from its Phase III RASolute 302 clinical trial. The study evaluated daraxonrasib, an oral multiselective, noncovalent GTP-bound inhibitor, in patients with pancreatic ductal adenocarcinoma.

The results were striking. Patients receiving a 300 mg once-daily dose of single-agent daraxonrasib saw their median overall survival increase to 13.2 months. In contrast, those receiving the investigator’s choice of conventional chemotherapy had a median overall survival of 6.7 months. This represents a hazard ratio (HR) of 0.40 (P < .0001), effectively doubling the survival time for this patient population.

“A median survival of more than a year in the second-line setting really does get your attention,” said Brian Wolpin, MD, MPH, Principal Investigator and Director of the Hale Family Center for Pancreatic Cancer Research and Gastrointestinal Cancer Center at Dana-Farber Cancer Institute.

Understanding the Mechanism: How Daraxonrasib Works

To understand why daraxonrasib is a breakthrough, it’s necessary to understand the role of RAS. In most pancreatic cancers, a mutation in the RAS gene acts like a “stuck” light switch, keeping the signal for cell growth permanently turned on. This leads to the rapid, uncontrolled proliferation of tumor cells.

Daraxonrasib differs from previous attempts at inhibition in several key ways:

• Multiselective Targeting: It doesn’t just target one specific mutation. It targets RAS G12 mutations (including G12, G13 and Q61) as well as wild-type RAS.
• GTP-Bound Inhibition: It acts as a noncovalent inhibitor that targets the GTP-bound (active) state of the protein.
• Oral Administration: As an oral medication, it offers a more accessible delivery method than traditional intravenous chemotherapy.

The Path Toward Precision Medicine

The implications of these findings are vast because of the prevalence of these mutations. Dr. Wolpin noted that more than 90% of patients have a KRAS mutation, meaning the vast majority of patients could potentially benefit from drugs that block this signaling pathway.

While the RASolute 302 trial marks a major milestone, researchers are already looking toward the next challenge: resistance. In a review published in the journal Signal Transduction and Targeted Therapy, researchers from the Barbara Ann Karmanos Cancer Institute and Wayne State University, including Dr. Asfar Azmi, are exploring strategies to overcome therapeutic resistance. Their work specifically focuses on improving the effectiveness of KRAS inhibitors for patients with G12D and G12V mutations, which are common in pancreatic cancer.

Frequently Asked Questions

What is the difference between daraxonrasib and chemotherapy?

Conventional chemotherapy works by killing rapidly dividing cells throughout the body, which often leads to significant side effects. Daraxonrasib is a targeted therapy; it specifically seeks out the mutated RAS proteins that drive the cancer’s growth, potentially offering a more precise attack on the tumor with a different safety profile.

Is daraxonrasib available now?

The primary and final analysis of the RASolute 302 trial is scheduled to be presented during the Plenary Session of the 2026 ASCO Annual Meeting. Regulatory approval and general availability typically follow the presentation of such pivotal Phase 3 data.

Who is eligible for this treatment?

The trial focused on previously treated patients with pancreatic ductal adenocarcinoma who harbor the targeted RAS mutations. Patients should consult their oncologist to determine if their specific tumor profile matches the targets of this medication.

Looking Ahead

The transition of KRAS from “undruggable” to “targetable” represents one of the most significant leaps in oncology in recent years. While no single drug is a cure, the ability to double survival in a second-line setting provides a critical foundation. As researchers continue to develop combination therapies and strategies to prevent resistance, the goal is to move these inhibitors into earlier lines of treatment, potentially transforming pancreatic cancer from a rapid terminal diagnosis into a manageable condition.